Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial save search
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $6.03 2.03% 1.99% 670K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Jasper Therapeutics Announces Positive Clinical Data from a Phase I/II Trial of Briquilimab as a Conditioning Treatment in Sickle Cell Disease and Beta Thalassemia
Published: 2023-01-03 (Crawled : 14:00) - biospace.com/
JSPR | $22.08 -0.14% -0.14% 45K
|
|
| O: 210.62%
H: 153.33%
C: 82.67%
treatment disease trial therapeutics positive
Invivyd Announces Positive Initial Results from Ongoing CANOPY Phase 3 Pivotal Clinical Trial Investigating VYD222 for the Prevention of COVID-19
Published: 2023-12-18 (Crawled : 12:00) - globenewswire.com
IVVD | $2.13 -6.17% -6.57% 390K
|
Manufacturing
|
| O: 23.93%
H: 133.17%
C: 77.72%
vyd222 covid-19 positive ongoing trial results
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
Published: 2021-11-23 (Crawled : 13:30) - biospace.com/
APVO | $0.6827 -7.27% -7.84% 570K
|
Health Technology
|
| O: 25.38%
H: 132.18%
C: 79.07%
treatment myeloid leukemia phase 1 expansion phase 1b leukemia trial therapeutics apvo436 acute myeloid leukemia phase 2b
Greenwich LifeSciences Hires Industry Expert, Dr. Jaye Thompson, to Manage Phase III Clinical Trial for Recurring Breast Cancer
Published: 2021-03-08 (Crawled : 12:00) - biospace.com/
GLSI | $12.6 -4.11% -4.29% 29K
|
Health Technology
|
| O: 0.04%
H: 130.25%
C: 61.67%
cancer breast cancer trial
BioCardia Anticipates DSMB Feedback on Interim Data From Pivotal Phase 3 CardiAMP Heart Failure Trial
Published: 2020-12-14 (Crawled : 13:05) - globenewswire.com
BCDA P | $0.376 -2.56% 64K
|
Health Technology
|
| O: 10.28%
H: 123.47%
C: 44.05%
heart phase 3 trial cardiamp
Initial Data from Allarity’s Phase 2 Trial of IXEMPRA® Indicate Potential for Improved Clinical Benefit in DRP®-Selected Metastatic Breast Cancer Patients
Published: 2023-07-05 (Crawled : 14:00) - globenewswire.com
ALLR | $1.37 -3.52% -3.65% 260K
|
n/a
|
| O: -1.59%
H: 117.58%
C: 33.55%
ixempra breast indicate cancer trial potential
Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity
Published: 2021-03-15 (Crawled : 13:00) - biospace.com/
RUBY | $0.057 -99.3% 760K
|
Health Technology
|
| O: 9.01%
H: 116.14%
C: 69.12%
solid tumors ongoing phase 1 trial phase 3 phase 2
Kiromic BioPharma and Beverly Hills Cancer Center Enter Clinical Trial Agreement
Published: 2023-10-23 (Crawled : 13:00) - biospace.com/
KRBP | $2.64 -90.21% 360
|
Health Technology
|
| O: -3.52%
H: 111.44%
C: 40.92%
cancer biopharma trial agreement
PepGen Reports Positive Data from Phase 1 Trial of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy
Published: 2022-09-28 (Crawled : 11:00) - biospace.com/
PEPG | $11.7 -0.17% -0.17% 20K
|
|
| O: 16.92%
H: 111.18%
C: 79.77%
edo51 treatment trial duchenne positive phase 1
bioAffinity Technologies Announces Publication of Results of Clinical Trial in Peer-Reviewed Journal Respiratory Research
Published: 2023-01-24 (Crawled : 15:00) - biospace.com/
BIAF | $2.4 -7.34% -7.92% 110K
|
|
| O: 20.13%
H: 108.9%
C: 46.07%
research respiratory trial results publication
Morphic Reports Positive Interim Results from Single Ascending Dose Phase 1 Clinical Trial of MORF-057
Published: 2021-03-01 (Crawled : 12:03) - globenewswire.com
MORF | $27.73 -3.55% -3.68% 330K
|
Health Technology
|
| O: 24.45%
H: 106.67%
C: 88.56%
phase 1 positive results trial phase 3 phase 2
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Published: 2021-01-27 (Crawled : 12:00) - globenewswire.com
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -1.12%
H: 0.1%
C: -1.6%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: -0.78%
H: 0.45%
C: -1.66%
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: -7.13%
H: 96.21%
C: 15.59%
covid ev biotech trial
Therapeutic Solutions International Secures Financing to Complete Current Phase III Stem Cell Clinical Trial
Published: 2022-09-20 (Crawled : 17:00) - biospace.com/
TSOI | $0.0007 0.0% 23M
|
Manufacturing
|
| O: 0.99%
H: 93.14%
C: 32.35%
solutions trial international
Reviva Announces Full Details of Positive Phase 2 Clinical Trial Results for Acute Schizophrenia
Published: 2021-04-26 (Crawled : 11:00) - biospace.com/
RVPH | $3.02 -1.31% -1.32% 78K
|
|
| O: 14.58%
H: 91.92%
C: 75.76%
phase 2 schizophrenia positive results trial trial results
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma
Published: 2023-12-12 (Crawled : 21:00) - globenewswire.com
CCCC | $6.47 -6.23% -6.65% 1M
|
Health Technology
|
| O: 35.9%
H: 89.62%
C: 73.27%
cft7455 positive trial therapeutics
Aclarion Announces Publication of 2YR Outcomes in Groundbreaking Clinical Trial
Published: 2023-04-24 (Crawled : 14:00) - biospace.com/
ACON | $0.2818 1.4% 48K
|
n/a
|
| O: 73.0%
H: 85.16%
C: 0.0%
publication trial
OpGen Announces Positive Top Line Data from Clinical Trial for Unyvero Urinary Tract Infection Panel
Published: 2022-12-13 (Crawled : 13:00) - ir.opgen.com
OPGN | $0.581 -5.22% -5.51% 170K
|
Commercial Services
|
| O: 96.32%
H: 84.47%
C: -5.87%
trial positive infection
Initial Data from Ongoing Phase 1 Trial of VIR-3434 for Chronic Hepatitis B Virus Infection Demonstrates Significant and Rapid Reduction in Hepatitis B Surface Antigen
Published: 2021-01-26 (Crawled : 13:03) - globenewswire.com
VIR | $8.04 -1.11% -1.12% 770K
|
Health Technology
|
| O: 1.37%
H: 73.96%
C: 71.96%
hepatitis trial phase 3 phase 1 phase 2 injection ongoing infections chronic hepatitis b
Positive Phase 2 Topaz Trial Extension Data Demonstrate Sizable and Sustained Motor Function Improvement at 24 Months with Apitegromab for Non-Ambulatory Patients with Types 2 and 3 Spinal Muscular Atrophy (SMA)
Published: 2022-06-17 (Crawled : 17:00) - biospace.com/
SRRK 4 | $14.11 -4.6% -4.82% 430K
|
Health Technology
|
| O: 4.12%
H: 73.52%
C: 6.52%
extension trial positive muscular atrophy
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.